Junshi Biosciences Wins China NMPA Approval for Loqtorzi HER2‑Urothelial Cancer Combo

Why It Matters

The NMPA’s endorsement of Loqtorzi signals a shift toward biomarker‑driven therapies in China’s oncology market, where most approvals have historically been indication‑agnostic. By delivering a clear survival advantage, the combo challenges the entrenched chemotherapy paradigm and may accelerate adoption of HER2 testing in urothelial cancer, a practice still limited in many Chinese hospitals. Moreover, the approval underscores Junshi Biosciences’ capacity to translate domestic clinical data into regulatory success, setting a precedent for other Chinese biotech firms seeking to commercialize precision medicines at scale. Beyond the immediate therapeutic benefit, Loqtorzi’s entry could influence pricing dynamics and reimbursement frameworks. If payers recognize the OS and PFS gains as cost‑effective, they may be more willing to fund high‑price antibody‑drug conjugates, paving the way for future innovative combos. The move also heightens competitive pressure on multinational companies, prompting them to prioritize Chinese trials and local partnerships to retain market relevance.

Key Takeaways

• Junshi Biosciences received NMPA approval for Loqtorzi (toripalimab + disitamab vedotin) in HER2‑positive advanced urothelial carcinoma.
• Phase III RC48‑C016 trial showed median PFS of 13.1 months vs 6.5 months (HR 0.36) and median OS of 31.5 months vs 16.9 months (HR 0.54).
• Objective response rate reached 76.1 % compared with 50.2 % for standard chemotherapy.
• Safety profile was significantly better than conventional chemotherapy, supporting first‑line use.
• Approval creates China’s first HER2‑targeted urothelial cancer therapy, expanding the precision‑oncology toolbox.

Pulse Analysis

Loqtorzi’s clearance marks a watershed moment for China’s biotech sector, illustrating how domestic firms can leverage targeted‑therapy platforms to meet unmet clinical needs. Historically, Chinese oncology approvals have skewed toward generic chemotherapies or broad‑spectrum immunotherapies. By delivering a dual‑primary endpoint success in a Phase III trial, Junshi demonstrates that rigorous, biomarker‑selected studies can achieve regulatory traction, potentially encouraging other Chinese innovators to pursue similar designs.

From a market perspective, the therapy’s survival advantage could reshape first‑line standards, especially if reimbursement bodies adopt value‑based pricing models that reward outcomes. The 2‑fold OS improvement suggests a compelling health‑economic case, but the ultimate pricing strategy will dictate adoption speed. Competitors with HER2‑directed ADCs, such as trastuzumab‑deruxtecan, may accelerate their Chinese filings, intensifying head‑to‑head competition. Junshi’s domestic manufacturing and distribution network provide a logistical edge, yet scaling production to meet national demand will be critical.

Looking forward, the real test will be Loqtorzi’s performance in the real‑world setting. Post‑marketing surveillance will reveal whether the safety and efficacy observed in the controlled trial translate across diverse patient populations. If successful, Junshi could leverage the data to seek approvals in other HER2‑expressing cancers, expanding its pipeline and reinforcing China’s emergence as a hub for precision oncology innovation.